Asensus Surgical develops robotic surgery systems and technology to provide real-time surgical insights and enhance decision-making in the operating room. The company is self-described as a pioneer in the use of Augmented Intelligence in surgery.

Asensus Surgical

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.

COM:ASENSUS

Asensus Surgical

Last Close

0.35

21/08 20:00

Market Cap

91.27M

Beta: -

Volume Today

3.94M

Avg: -

Filings Not Available